Sun Pharmaceutical Industries Ltd. exhibits solid growth and profitability metrics but is overshadowed by peers with better valuations and returns. The analysis reveals several companies outperforming in key areas such as growth and profitability, while some present attractive value opportunities despite high valuations for others.

• • Sun Pharma has a moderate revenue growth of 8.42%, while Mankind Pharma leads with 18.12%.
• • Cipla shows the best EPS (66.76) while Divi's Laboratories has the highest 3-year EPS growth of 82.53.
• • Torrent Pharmaceuticals boasts the highest ROE at 25.38%, and Zydus Lifesciences has a solid ROCE of 24.90%.
• • Cipla has the lowest PE at 23.73, while Sun Pharma is the highest at 87.59, indicating potential overvaluation.
• • Divi's Laboratories has impressive EBITDA margin (37.14%) and a high profit margin (20.40%), both leading the group.
• • The lowest debt-equity ratio is held by Divi's Laboratories (0.00), highlighting its strong financial position.